Inspra Articles
Heart meeting hears disappointing results for J&J/Scios Natrecor; strong findings for Pfizer’s Inspra
15 November 2010
Pfizer moves to keep market share in Japan
24 March 2008
Nine NCEs added to Japan's NHI drug list
8 October 2007
Japanese regulator gives nod to three new drugs
21 May 2007
Australia OKs Inspra
19 December 2005
Pfizer receives approval for Inspra in the Netherlands
29 March 2004
FDA clears Pfizer's Inspra for CHF
20 October 2003
Pfizer's Inspra cuts HF deaths 15%
8 September 2003
2002's crop of new product launches backs up R&D fears
10 February 2003
Pharmacia's Inspra meets EPHESUS primary endpoints
6 January 2003
Pharmacia EPS up by 8% in 2nd-quarter
29 July 2002
Pharmacia intent on "doubling Japanese sales"
24 June 2002
Stock Commentary - Europe
3 June 2002
New eplerenone data support efficacy
27 May 2002
Pharmacia sales take a dip in first quarter
29 April 2002
Pharmacia's eplerenone better in combination
1 April 2002
Pharmacia 4th-qtr profits take a dip but Celebrex still selling well
11 February 2002
Review of eplerenone gets underway in USA
11 February 2002
Pharmacia's product pipeline; what's in store after Celebrex?
29 November 2001
Actelion well-placed for success with endothelin antagonists for heart
21 September 2000
Searle to conduct global Phase III trial of eplerenone
29 March 2000
Searle begins pivotal trial of eplerenone
3 February 2000
Searle begins pivotal trial of eplerenone
28 January 2000
Showing 1-30 of 30 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
